The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis.
Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.
The study examined high concentrations of consumed siRNAs and dsRNAs targeting the mouse ortholog of a known pest-control gene.
The therapy is the company's first to feature an optimized version of its GalNAc conjugate delivery technology.
According to its CEO, Silence is aiming to expand into a "full-functioning biotech" with more than just a single product.
Officials said the firm remains confident in its HBV drug despite investors' negative reaction to Phase IIa data.
The company is conducting in vivo testing with the La Jolla Institute for Allergy and Immunology.
The RNAi molecules have been licensed to Solstice Biologics, which is developing them for therapeutic applications.
The trial is set to run in Australia.
NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its third-quarter financial results, posting a net loss essentially flat with last year as expenses held steady.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.